Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Research Solutions (RSSS) Cash & Equivalents (2016 - 2025)

Research Solutions (RSSS) has disclosed Cash & Equivalents for 16 consecutive years, with $12.3 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 59.23% to $12.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $12.3 million through Dec 2025, up 59.23% year-over-year, with the annual reading at $12.2 million for FY2025, 100.45% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $12.3 million at Research Solutions, up from $12.0 million in the prior quarter.
  • The five-year high for Cash & Equivalents was $13.5 million in Q2 2023, with the low at $2.7 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $9.8 million, with a median of $10.7 million recorded in 2021.
  • The sharpest move saw Cash & Equivalents plummeted 76.05% in 2023, then skyrocketed 185.48% in 2024.
  • Over 5 years, Cash & Equivalents stood at $10.7 million in 2021, then increased by 5.46% to $11.3 million in 2022, then tumbled by 76.05% to $2.7 million in 2023, then surged by 185.48% to $7.7 million in 2024, then skyrocketed by 59.23% to $12.3 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $12.3 million, $12.0 million, and $12.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.